Erector Spinae Block Versus Thoracic Paravertebral Block for Acute Thoracic Herpes Zoster

Tanta University

Status and phase: Unknown; Phase 4

Conditions: Erector Spinae Plane Block; Thoracic Paravertebral Block; Acute Thoracic Herpes Zoster; Pain Relief

Treatments: Procedure: Thoracic Paravertebral Block; Drug: Control Rx; Procedure: Erector Spinae Block

Study type: Interventional

Funder types: Other

Identifiers

NCT04656821

32720/11/18

Details and patient eligibility

About

The aim of this research is to study and compare the efficacy and safety of single injection erector spinae plane block and thoracic paravertebral block in prevention of post herpetic neuralgia in patients with acute thoracic herpes zoster.

Enrollment: 90 estimated patients

Sex: All

Ages: 51 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Over 50 years of age
• Chest wall herpetic eruption of less than one week
• Moderate or severe pain

Exclusion criteria

• Patient refusal
• Eruption more than one week duration
• Patients who will not receive appropriate anti-viral therapy
• Patients with mild pain
• Infection at the site of injection
• Patients with a history of renal, hepatic diseases, coagulopathy, steroid therapy, malignancies.
• Patient taking chemotherapy and/or radiotherapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

Control Group

Active Comparator group

Description:

Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.

Treatment:

Drug: Control Rx

Erector Spinae Block (ESB) group

Experimental group

Description:

Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.

Treatment:

Procedure: Erector Spinae Block

Thoracic Paravertebral Block group

Experimental group

Description:

Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography

Treatment:

Procedure: Thoracic Paravertebral Block